NCT04927299View on ClinicalTrials.gov

Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

August 15, 2023

Study Completion Date

September 11, 2023

Conditions
Essential Arterial Hypertension
Interventions
DRUG

Losartan/Chlorthalidone in fixed dose

1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg

DRUG

Losartan + hydrochlorothiazide in fixed dose

1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg

Trial Locations (1)

11000

Laboratorio Silanes, S.A. de C.V., Mexico City

All Listed Sponsors
lead

Laboratorios Silanes S.A. de C.V.

INDUSTRY